PICO Portalanswers from OpenAlex & ORCID
Primo N. Lara
ResearcherPublications, citations & collaboration network
Primo N. Lara is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Primo N. Lara have?
PICO Portalindexed works
Primo N. Lara has 899 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Primo N. Lara have?
PICO Portalcitation count
Primo N. Lara has 25,295 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Primo N. Lara?
PICO Portalh-index
Primo N. Lara has an h-index of 73 in OpenAlex.
What is the i10-index of Primo N. Lara?
PICO Portali10-index
Primo N. Lara has an i10-index of 300 in OpenAlex.
What is the ORCID of Primo N. Lara?
PICO Portalorcid
The ORCID for Primo N. Lara is on the source record.
What is the OpenAlex record for Primo N. Lara?
PICO Portalopenalex
The OpenAlex for Primo N. Lara is on the source record.
What are the most-cited papers on Primo N. Lara?
PICO Portalmost cited works
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna L. Berry, Carol M. Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
David A. Quigley, Ha X. Dang, Shuang G. Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J. Alumkal, Adam Foye, Vishal Kothari, Marc D. Perry, Adina Bailey, Denise Playdle, Travis J. Barnard, Li Zhang, Jin Zhang, Jack Youngren, Marcin Cieślik, Abhijit Parolia, Tomasz M. Beer, George Thomas, Kim N., Martin Gleave, Nathan A. Lack, Amina Zoubeidi, Robert E. Reiter, Matthew B. Rettig, Owen N. Witte, Charles J. Ryan, Lawrence Fong, Won Kim, Terence W. Friedlander, Jonathan Chou, Haolong Li, Rajdeep Das, Hui Li, Ruhollah Moussavi-Baygi, Hani Goodarzi, Luke A. Gilbert, Primo N. Lara, Christopher P. Evans, Theodore C. Goldstein, Joshua M. Stuart, Scott A. Tomlins, Daniel E. Spratt, R. Keira Cheetham, Donavan T. Cheng, Kyle Kai‐How Farh, Julian Gehring, Jörg Hakenberg, Arnold Liao, Philip G. Febbo, John Shon, Brad Sickler, Serafim Batzoglou, Karen E. Knudsen, Housheng Hansen He, Jiaoti Huang, Alexander W. Wyatt, Scott M. Dehm, Alan Ashworth, Arul M. Chinnaiyan, Christopher A. Maher, Eric J. Small, Felix Y. Feng
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Payal Kapur, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela D. Motter
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Louis M. Fink, Tong Xu, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci, J. Paul Monk, Ram H. Datar, Mark Garzotto, Philip C. Mack, Primo N. Lara, Celestia S. Higano, Maha Hussain, Ian M. Thompson, Richard J. Côté, Nicholas J. Vogelzang
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara, Jean‐Yves Douillard, Kazuhiko Nakagawa, Joachim von Pawel, Mark J. McKeage, István Albert, György Losonczy, Martin Reck, Dae Seog Heo, Xiaolin Fan, Abderrahim Fandi, Giorgio V. Scagliotti